E-LIB Suche - Ergebnisse für: Rubinstein, Maria

1

A phase 2 trial of zanidatamab in HER2-overexpressed advanc..:

Lumish, Melissa ; Chui, M. Herman ; Zhou, Qin...
Gynecologic Oncology. 182 (2024) - p. 75-81 , 2024

Link: https://doi.org/10.1016/..

2

Real-world outcomes and adverse events when using combinati..:

Zammarrelli, William ; Ma, Weining ; Espino, Kevin...
Gynecologic Oncology. 176 (2023) - p. S79-S80 , 2023

Link: https://doi.org/10.1016/..

3

Comprehensive analysis of germline drivers in endometrial c..:

Gordhandas, Sushmita ; Rios-Doria, Eric ; Cadoo, Karen A...
JNCI: Journal of the National Cancer Institute. 115 (2023) 5 - p. 560-569 , 2023

Link: https://doi.org/10.1093/..

4

Germline drivers of gynecologic carcinosarcoma (2274):

Sia, Tiffany ; Birsoy, Ozge ; Kemel, Yelena...
Gynecologic Oncology. 176 (2023) - p. S299-S300 , 2023

Link: https://doi.org/10.1016/..

5

ADAGIO: A phase IIb, open-label, single-arm, multicenter st..:

Liu, Joyce ; Colombo, Nicoletta ; Oza, Amit...
Gynecologic Oncology. 176 (2023) - p. S33-S35 , 2023

Link: https://doi.org/10.1016/..

6

Germline drivers of gynecologic carcinosarcomas:

Sia, Tiffany Y. ; Gordhandas, Sushmita B. ; Birsoy, Ozge...
Gynecologic Oncology. 174 (2023) - p. 34-41 , 2023

Link: https://doi.org/10.1016/..

7

Looking beyond carboplatin and paclitaxel for the treatment..:

Rubinstein, Maria ; Shen, Sherry ; Monk, Bradley J....
Gynecologic Oncology. 167 (2022) 3 - p. 540-546 , 2022

Link: https://doi.org/10.1016/..

8

Retreatment with carboplatin and paclitaxel for recurrent e..:

Rubinstein, Maria ; Halpenny, Darragh ; Makker, Vicky...
Gynecologic Oncology Reports. 28 (2019) - p. 120-123 , 2019

Link: https://doi.org/10.1016/..

9

Lenalidomide in the treatment of Rosai Dorfman disease—a fi..:

Rubinstein, Maria ; Assal, Amer ; Scherba, Marina...
American Journal of Hematology. 91 (2016) 2 - p. , 2016

Link: https://doi.org/10.1002/..

10

Nivolumab for mismatch-repair-deficient or hypermutated gyn..:

Friedman, Claire F. ; Manning-Geist, Beryl L. ; Zhou, Qin...
Nature Medicine. 30 (2024) 5 - p. 1330-1338 , 2024

Link: https://doi.org/10.1038/..

11

Adverse events and oncologic outcomes with combination lenv..:

Zammarrelli III, William A. ; Ma, Weining ; Espino, Kevin...
Gynecologic Oncology. 178 (2023) - p. 27-35 , 2023

Link: https://doi.org/10.1016/..

12

Durvalumab with or without tremelimumab in patients with pe..:

Rubinstein, Maria M. ; Doria, Eric Rios ; Konner, Jason...
Gynecologic Oncology. 169 (2023) - p. 64-69 , 2023

Link: https://doi.org/10.1016/..

13

A phase I open-label study of selinexor with paclitaxel and..:

Rubinstein, Maria M. ; Grisham, Rachel N. ; Cadoo, Karen...
Gynecologic Oncology. 160 (2021) 1 - p. 71-76 , 2021

Link: https://doi.org/10.1016/..

14

Targeting obesity-related dysfunction in hormonally driven ..:

Rubinstein, Maria M. ; Brown, Kristy A. ; Iyengar, Neil M.
British Journal of Cancer. 125 (2021) 4 - p. 495-509 , 2021

Link: https://doi.org/10.1038/..

15

Baseline risk of hematologic malignancy at initiation of fr..:

Navitski, Anastasia ; Al-Rawi, Duaa H. ; Liu, Ying...
Gynecologic Oncology Reports. 38 (2021) - p. 100873 , 2021

Link: https://doi.org/10.1016/..